Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL

被引：11

作者：

Pusztai, Lajos ^{[1
]}

Han, Hyo S. ^{[2
]}

Yau, Christina ^{[3
]}

Wolf, Denise ^{[4
]}

Wallace, Anne M. ^{[5
]}

Shatsky, Rebecca ^{[5
]}

Helsten, Teresa ^{[5
]}

Boughey, Judy C. ^{[6
]}

Haddad, Tufia ^{[6
]}

Stringer-Reasor, Erica ^{[7
]}

Falkson, Carla ^{[7
]}

Chien, A. Jo ^{[4
]}

Mukhtar, Rita ^{[4
]}

Elias, Anthony ^{[8
]}

Virginia, Borges ^{[8
]}

Nanda, Rita ^{[9
]}

Yee, Douglas ^{[10
]}

Kalinsky, Kevin ^{[11
]}

Albain, Kathy S. ^{[12
]}

Muller, Aixa Soyano ^{[2
]}

Kemmer, Kathleen ^{[13
]}

Clark, Amy S. ^{[14
]}

Isaacs, Claudine ^{[15
]}

Thomas, Alexandra ^{[16
]}

Hylton, Nola ^{[4
]}

Symmans, W. Fraser ^{[17
]}

Perlmutter, Jane ^{[18
]}

Melisko, Michelle ^{[4
]}

Rugo, Hope S. ^{[4
]}

Schwab, Richard ^{[19
]}

Wilson, Amy ^{[20
]}

Singhrao, Ruby ^{[4
]}

Asare, Smita ^{[20
]}

van't Veer, Laura J. ^{[4
]}

DeMichele, Angela M. ^{[14
]}

Sanil, Ashish ^{[21
]}

Berry, Donald A. ^{[21
]}

Esserman, Laura J. ^{[4
]}

机构：

[1] Yale Univ, New Haven, CT USA

[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[3] Buck Inst Age Res, Novato, CA USA

[4] Univ Calif San Francisco, San Francisco, CA 94143 USA

[5] Univ Calif San Diego, La Jolla, CA 92093 USA

[6] Mayo Clin Minnesota, Rochester, MN USA

[7] Univ Alabama Birmingham, Birmingham, AL USA

[8] Univ Colorado Denver, Aurora, CO USA

[9] Univ Chicago, Chicago, IL 60637 USA

[10] Univ Minnesota, Minneapolis, MN USA

[11] Columbia Univ, New York, NY USA

[12] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA

[13] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[14] Univ Penn, Philadelphia, PA 19104 USA

[15] Georgetown Univ, Washington, DC USA

[16] Wake Forest Univ, Salem, NC USA

[17] MD Anderson Canc Ctr, Houston, TX USA

[18] Gemini Grp, Ann Arbor, MI USA

[19] Univ Calif San Diego, San Diego, CA 92103 USA

[20] Quantum Leap Healthcare Collaborat, San Francisco, CA USA

[21] Berry Consultants, Austin, TX USA

来源：

CANCER RESEARCH | 2020年 / 80卷 / 16期

关键词：

D O I：

10.1158/1538-7445.AM2020-CT011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT011

引用

页数：3

共 50 条

[1] Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Pusztai, Lajos
Yau, Christina
Wolf, Denise M.
Han, Hyo S.
Du, Lili
Wallace, Anne M.
String-Reasor, Erica
Boughey, Judy C.
Chien, A. Jo
Elias, Anthony D.
Beckwith, Heather
Nanda, Rita
Albain, Kathy S.
Clark, Amy S.
Kemmer, Kathleen
Kalinsky, Kevin
Isaacs, Claudine
Thomas, Alexandra
Shatsky, Rebecca
Helsten, Theresa L.
Forero-Torres, Andres
Liu, Minetta C.
Brown-Swigart, Lamorna
Petricoin, Emmanuel F.
Wulfkuhle, Julia D.
Asare, Smita M.
Wilson, Amy
Singhrao, Ruby
Sit, Laura
Hirst, Gillian L.
Berry, Scott
Sanil, Ashish
Asare, Adam L.
Matthews, Jeffrey B.
Perlmutter, Jane
Melisko, Michelle
Rugo, Hope S.
Schwab, Richard B.
Symmans, W. Fraser
Yee, Doug
Van't Veer, Laura J.
Hylton, Nola M.
DeMichele, Angela M.
Berry, Donald A.
Esserman, Laura J.
[J]. CANCER CELL, 2021, 39 (07) : 989 - +
[2] Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Schwab, Richard
Clark, Amy S.
Yau, Christina
Hylton, Nola
Li, Wen
Wolfe, Denise
Chien, A. Jo
Wallace, Anne M.
Forero-Torres, Andres
Stringer-Reasor, Erica
Nanda, Rita
Jaskowiak, Nora
Boughey, Judy
Haddad, Tufia
Han, Heather S.
Lee, Catherine
Albain, Kathy
Isaacs, Claudine
Elias, Anthony D.
Ellis, Erin D.
Shah, Payal
Lang, Julie E.
Lu, Janice
Tripathy, Debasish
Kemmer, Kathleen
Yee, Douglas
Haley, Barbara
Majure, Melanie
Roesch, Erin
Vaklavas, Christos
Ewing, Cheryl
Helsten, Teresa
Symmans, W. Fraser
Perlmutter, Jane
Rugo, Hope S.
Melisko, Michelle
Wilson, Amy
Singhrao, Ruby
van't Veer, Laura
De Michele, Angela
Asare, Smita
Berry, Don
Esserman, Laura J.
[J]. CANCER RESEARCH, 2019, 79 (13)
[3] Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Beckwith, Heather
Schwab, Richard
Yau, Christina
Stringer-Reasor, Erica
Wei, Shi
Chien, A. Jo
Albain, Kathy S.
Kalinsky, Kevin
Wallace, Anne
Elias, Anthony
Yee, Douglas
Clark, Amy S.
Boughey, Judy C.
Han, Heather
Nanda, Rita
Isaacs, Claudine
Mitri, Zahi
Lang, Julie E.
Thomas, Alexandra
Sanft, Tara
DeMichele, Angela
Perlmutter, Jane
Rugo, Hope S.
Hylton, Nola M.
Symmans, W. Fraser
Melisko, Michelle E.
van't Veer, Laura J.
Wilson, Amy
Asare, Smita M.
Sanil, Ashish
Berry, Donald A.
Esserman, Laura J.
[J]. CANCER RESEARCH, 2021, 81 (04)
[4] Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer: Results from the neoadjuvant I-SPY 2 trial
Helsten, Teresa L.
Lo, Shelly S.
Yau, Christina
Kalinsky, Kevin
Elias, Anthony D.
Wallace, Anne M.
Chien, A. Jo
Lu, Janice
Lang, Julie E.
Albain, Kathy S.
Stringer-Reasor, Erica
Clark, Amy S.
Boughey, Judy C.
Ellis, Erin D.
Yee, Douglas
DeMichele, Angela
Isaacs, Claudine
Perlmutter, Jane
Rugo, Hope S.
Schwab, Richard
Hylton, Nola M.
Symmans, W. Fraser
Melisko, Michelle E.
van't Veer, Laura J.
Wilson, Amy
Singhrao, Ruby
Asare, Smita M.
Sanil, Ashish
Berry, Donald A.
Esserman, Laura J.
[J]. CANCER RESEARCH, 2020, 80 (04)
[5] Evaluation of Tucatinib plus (Paclitaxel plus Pertuzumab plus Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Potter, David A.
Roesch, Erin
Yau, Christina
Lu, Ruixiao
Wolf, Denise
Samson, Susan
Stafford, Debra
Albain, Kathy S.
Isaacs, Claudine
Trivedi, Meghana
Yee, Douglas
Boughey, Judy
Thomas, Alexandra
Chien, A. Jo
Hylton, Nola
Li, Wen
DeMichele, Angela
Perlmutter, Jane
Symmans, W. Fraser
Hershman, Dawn L.
Melisko, Michelle
Veer, Laura J. van ' t
Wilson, Amy
Asare, Smita M.
Berry, Donald A.
Schwab, Richard
Rugo, Hope S.
Esserman, Laura J.
[J]. CANCER RESEARCH, 2022, 82 (04)
[6] Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Liu, Minetta C.
Robinson, Patricia A.
Yau, Christina
Wallace, Anne M.
Chien, A. Jo
Stringer-Reasor, Erica
Nanda, Rita
Yee, Douglas
Albain, Kathy S.
Boughey, Judy C.
Han, Heather S.
Elias, Anthony D.
Kalinsky, Kevin
Clark, Amy S.
Kemmer, Kathleen
Isaacs, Claudine
Lang, Julie E.
Lu, Janice
Sanft, Tara
DeMichele, Angela
Hylton, Nola M.
Melisko, Michelle E.
Perlmutter, Jane
Rugo, Hope S.
Schwab, Richard
Symmans, W. Fraser
van't Veer, Laura J.
Haugen, Patricia K.
Wilson, Amy
Singhrao, Ruby
Asare, Smita
Sanil, Ashish
Berry, Donald A.
Esserman, Laura J.
[J]. CANCER RESEARCH, 2020, 80 (04)
[7] Biomarkers predicting response to durvalumab combined with olaparib in the neoadjuvant I-SPY 2 TRIAL for high-risk breast cancer
Wolf, Denise M.
Yau, Christina
Brown-Swigart, Lamorna
O'Grady, Nick
Hirst, Gillian
Sit, Laura
Asare, Smita
Berry, Don
Esserman, Laura
Han, Hyo
Pusztai, Lajos
van 't Veer, Laura
[J]. CANCER RESEARCH, 2021, 81 (04)
[8] Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial.
Chien, Amy Jo
Soliman, Hatem Hussein
Ewing, Cheryl Ann
Boughey, Judy Caroline
Campbell, Michael J.
Rugo, Hope S.
Wallace, Anne M.
Albain, Kathy S.
Stringer-Reasor, Erica Michelle
Church, An L.
Kalinsky, Kevin
Elias, Anthony D.
Mitri, Zahi Ibrahim
Clark, Amy Sanders
Nanda, Rita
Thomas, Alexandra
Yau, Christina
Berry, Donald A.
Esserman, Laura
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[9] The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL
Albain, K. S.
Leyland-Jones, B.
Symmans, F.
Paoloni, M.
van't Veer, L.
DeMichele, A.
Buxton, M.
Hylton, N.
Yee, D.
Clennell, J. Lyandres
Yau, C.
Sanil, A.
Berry, D.
Esserman, L.
[J]. CANCER RESEARCH, 2016, 76
[10] PD11-01 Evaluation of the PD-1 Inhibitor Cemiplimab in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Stringer-Reasor, Erica
Shatsky, Rebecca A.
Chien, Jo
Wallace, Anne
Boughey, Judy C.
Albain, Kathy S.
Han, Hyo S.
Nanda, Rita
Isaacs, Claudine
Kalinsky, Kevin
Mitri, Zahi
Clark, Amy S.
Vaklavas, Christos
Thomas, Alexandra
Trivedi, Meghna S.
Lu, Janice
Asare, Smita
Lu, Ruixiao
Pitsouni, Maria
Wilson, Amy
Perlmutter, Jane
Rugo, Hope
Schwab, Richard
Symmans, W. Fraser
Hylton, Nola M.
Van 't Veer, Laura
Yee, Douglas
DeMichele, Angela
Berry, Donald
Esserman, Laura J.
[J]. CANCER RESEARCH, 2023, 83 (05)

← 1 2 3 4 5 →